Reaction profile
The FDA adverse-event record for optic nerve disorder
59 FDA reports name optic nerve disorder, a lower-volume reaction in the CVM extract (VeDDRA 450). Plate stamps and neighbourhood peers follow.
- #1664 of 2,481
- by report volume (all reactions)
- 59
- reports citing this reaction
- 15.3%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Optic nerve disorder has 59 reports now versus 59 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Optic nerve disorder changesFDA AER · VeDDRA plate
Code 450 VOL-LOW
VOL-LOW · DEATH-ELEV · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-LOW 59 reports
- DEATH-ELEV 15.3%
- MID-PACK #1664/2481
- PHOTO-FINISH Hypoaesthesia
- SPECIES-DOG Dog · 48
- DRUG-LEAD Milbemycin Oxime… · 10
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Hypoaesthesia (±0 reports)
Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.
Lower-volume neighbourhood around Optic nerve disorder
Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.
What the FDA AER plate says about Optic nerve disorder
Signature read: report volume at 59 (#1664 of 2,481) is the standout scale stamp on Optic nerve disorder. Report volume is lower-third scale: 59 named reports in the openFDA extract. 9 of 59 reports were death-coded (15.3% of named reports, not a population mortality rate). Nearest volume peer: Hypoaesthesia (±0 reports). Lead species Dog (48). Lead co-reported drug Milbemycin Oxime + Spinosad (10).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Milbemycin Oxime + Spinosad appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Optic nerve disorder, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (59 here).
Similar death-coded share
Nearest other reactions by death-coded share (15.3% here), distinct from the volume row.
What to do with this reaction
- Compare Optic nerve disorder's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →